Major β‐thalassemia (β‐TM) is one of the most common inherited hemolytic types of anemia
which is caused as a result of absent or reduced synthesis of β‐globin chains of …

Abstract β-Thalassemia (β-thal) is a type of hereditary anemia affecting hemoglobin (Hb)
synthesis causing severe chronic anemia in homozygous patients. Regular blood …

Silymarin, a flavonolignan complex isolated from Silybum marianum, has a strong
antioxidant, hepatoprotective, and iron chelating activities. The present study was designed …

Background: In β-thalassemia major (β-TM) patients, iron overload is one of the main causes
of inflammation. This study investigated whether use of silymarin could improve …

Objective Thalassemia is one of the most common genetic disorders worldwide. Chronic
blood transfusions treat the underlying anemia but may lead to iron toxicity. Effective iron …

Background & aims Blood transfusion therapy is lifesaving for individuals with β-thalassemia
major (β-TM). Iron burden following blood transfusion is the main cause of oxidative stress …

This study aimed to determine the potential iron‐chelating effects of silymarin in patients with
β‐thalassemia major receiving standard iron‐chelation therapy. We evaluated whether …

OBJECTIVE: Silymarin, a flavonolignan complex isolated from milk thistle, is a
cytoprotective, antioxidant, and hepatoprotective agent. The present study was designed to …

Background Beta thalassemia is an inherited hemoglobin disorder resulting in a severe,
chronic anemia requiring life-long blood transfusion that induces iron overload. Silymarin is …

Several immunological abnormalities have been characterized in β-thalassemia, many of
which are linked to or identified with cytokines. In this study, we investigated the serum …